UPDATE : Monday, September 7, 2020
상단여백
[Exclusive] Patent of osteoarthritis drug Invossa refused in Europe
Kolon TissueGene has failed to obtain a patent for Korea’s 29th novel drug ...
by Nam Doo-hyun  |  2018-10-30 16:04
라인
CrystalGenomics to change molecular targeted therapy from injection to oral drug in trials
CrystalGenomics said it would change the form of an investigational molecul...
by Nam Doo-hyun  |  2018-10-30 10:52
라인
‘Foreign investors fear Korean botox sales decline in China’
Foreign institutional investors fear that Korean makers of botulinum toxin ...
by Nam Doo-hyun  |  2018-10-29 16:52
라인
‘Bio Solution’s value to rise on arthritis cell therapy’
Bio Solution will be able to drive up its market capitalization once it obt...
by Nam Doo-hyun  |  2018-10-25 16:30
라인
Novartis struggles to restore sales of Alzheimer’s drug Exelon
Novartis has failed to restore the sales of Exelon, a patch for the treatme...
by Nam Doo-hyun  |  2018-10-25 11:04
라인
Will synthetic biology be vital in smart therapeutics?
Synthetic biology, which designs biological components and systems in new w...
by Nam Doo-hyun  |  2018-10-24 16:40
라인
Biotech shares tank amid nosediving of Seoul stocks
Biotech and pharmaceutical shares plunged on Tuesday, hurt mainly by the ov...
by Nam Doo-hyun  |  2018-10-24 11:35
라인
Anticoagulant Lixiana outpaces Eliquis in Q3 prescriptions
Daiichi Sankyo’s Lixiana (edoxaban), a latecomer in the non-vitamin K antag...
by Nam Doo-hyun  |  2018-10-23 16:10
라인
‘Antibody drug developer AbClon noteworthy’
AbClon, a developer of innovative antibody medicines, is likely to achieve ...
by Nam Doo-hyun  |  2018-10-22 14:49
라인
'Superbug' fears bring antibiotics developers under spotlight
Investors are paying keen attention to antibiotics developers amid growing ...
by Nam Doo-hyun  |  2018-10-22 11:53
라인
Bayer’s blood thinner wins broader indication for coronary artery disease
Bayer Korea said it has obtained approval for an expanded indication for Xa...
by Nam Doo-hyun  |  2018-10-19 16:34
라인
Dental implant firms anticipate sales growth in H2
With the new policy to reduce senior patients’ payment for dental implants,...
by Nam Doo-hyun  |  2018-10-18 14:52
라인
‘Korea needs to toughen crackdown on illegal brokers for medical tourism’
The government should enhance the punishment of illegal brokers who bring i...
by Nam Doo-hyun  |  2018-10-17 15:28
라인
Relaxing requirement for innovative drugmakers will benefit Samsung, SK’
A revision bill to ease requirements for the state designation of innovativ...
by Nam Doo-hyun  |  2018-10-17 14:38
라인
CrystalGenomics hopes to test new leukemia drug early next year
CrystalGenomics said it hoped to carry out a phase-1 clinical trial on new ...
by Nam Doo-hyun  |  2018-10-16 16:17
라인
Bio stocks listed under ‘tech exception policy’ perform better
Biotech and medical companies that went public under the Korea Exchange’s “...
by Nam Doo-hyun  |  2018-10-15 12:27
라인
Anticipation grows for Lenvima as new liver cancer drug
Eisai Korea’s Lenvima (lenvatinib), recently approved as a first-line treat...
by Nam Doo-hyun  |  2018-10-11 11:44
라인
‘Korea publishes many biotech papers but rarely links them to biz’
South Korea’s ranking in biotech competitiveness, announced by the U.S. sci...
by Nam Doo-hyun  |  2018-10-10 16:35
라인
More biotech stocks come in top 20 on KOSDAQ
The number of pharmaceutical and biotech firms within the top 20 companies ...
by Nam Doo-hyun  |  2018-10-10 11:20
라인
‘Medytox performance depends on Chinese regulations on peddlers’
Medytox’s performance in the fourth quarter will rely on the Chinese govern...
by Nam Doo-hyun  |  2018-10-08 16:59
여백
여백
여백
Back to Top